Telehealth MAT

Telehealth MAT

Collection:
Health Policy and Services Research
Series Title(s):
Innovation landscape series (California HealthCare Foundation)
Contributor(s):
California HealthCare Foundation, issuing body.
ST Advisors, issuing body.
Publication:
[Oakland, California] : California Health Care Foundation, June 2019
Language(s):
English
Format:
Text
Subject(s):
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
Telemedicine
California
United States
Genre(s):
Technical Report
Abstract:
The opioid epidemic claimed over 47,000 American lives in 2017, with a total economic cost of over $78 billion in 2013.2 Medication-assisted treatment (MAT) combines the use of FDA-approved medications--methadone, buprenorphine, and naltrexone--with behavioral therapy and is recognized as the most effective treatment method for lasting recovery from opioid use disorder (OUD). The Innovation Opportunity. The widespread adoption of MAT is hampered by a number of systemic barriers. The most notable difficulty is the significant shortage of authorized prescribers for these medications caused by regulatory hurdles requiring a license to prescribe, limits on patient panel sizes for buprenorphine prescribers, and reimbursement limitations. As a result, access to this life-saving treatment is limited. Telehealth offers a promising approach to reducing barriers to access to MAT. This brief provides an overview of telehealth for MAT. Eleven interviews were conducted with 11 organizations directly offering telehealth services nationally. Many are not yet expanding into MAT. Others are part of a developing, but nascent, telehealth MAT environment.
Copyright:
Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY-NC-ND license. (More information)
Extent:
1 online resource (1 PDF file (6 pages))
Illustrations:
Illustrations
NLM Unique ID:
101758636 (See catalog record)
Permanent Link:
http://resource.nlm.nih.gov/101758636